// App-Quantinova.ai

: INOTUZUMAB OZOGAMICIN (INO) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): OUTCOMES OF PATIENTS TREATED IN SALVAGE ONE WITH A LONG DURATION OF FIRST REMISSION

Researchers

Presenter

  • Matthias Stelljes

Principal Investigators

  • Elias Jabbour

  • Anjali Advani

  • Daniel J DeAngelo

  • David I Marks

  • Wendy Stock

  • Susan OBrien

  • Ryan D Cassaday

  • Tao Wang

  • Alexander Neuhof

  • Erik Vandendries

  • Hagop Kantarjian

Medical Centers

  • Universitatsklinikum Munster, Munster, Germany

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • University of Bristol, Bristol, United Kingdom

  • University of Chicago, Chicago, IL, United States

  • University of California, Davis, Davis, California, United States

  • University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA

  • Pfizer Groton CT United States

  • Pfizer Pharma GmbH, Berlin, Germany

  • Pfizer Inc,Cambridge,United States

Locations

  • Germany

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved